KMTS
Kestra Medical Technologies, Ltd. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$29.69Close
$1.7BMarket cap
$17.87 – $30.6152-week range
Dec 10, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Near its high 3% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
3%
1wk
up 3.2%
price change
1mo
up 4.9%
price change
12-month return
up 6%
market up 11% ·
its own down 5%
F-score
4 / 9
Weak
Altman Z
7.58
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
6.7×
price / book
Earnings yield
down 8.0%
EBIT / enterprise value
Cheaper than
15%
of the market · expensive
Revenue growth
up 59%
year on year
EPS growth
—
latest quarter
Sales growth
up 60%
latest quarter · -6 pts
ROE
down 57%
return on equity
Free cash margin
down 123%
-$116.6M FCF
D/E
0.16
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
- gross margin widened
Repair signals
- Gross margin 40.5% → 51.4%
Trade setup
ATR%
5.4%
$1.59 a day · 2×ATR $26.50
RS
79 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.22
50 sessions
Implied move
—
no option chain · report Dec 10, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 13.7% over the year, from 51m to 58m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Sep 14, 2026
Results reaction
Sep 14, 2026+11% vs market2 sessions after results
Financials
- Gross 51%
- Net -138%
- Free cash -123%
- Cash
- Long-term debt
| FY2024Apr 30, 2024 | FY2025Apr 30, 2025 | FY2026Apr 30, 2026 | |
|---|---|---|---|
| Revenue | $27.8M | $59.8M | $95.1M |
| Gross margin | 1% | 40% | 51% |
| Operating income | -$85.1M | -$106.4M | -$134.7M |
| Net income | -$94.1M | -$113.8M | -$131.6M |
| Net margin | -338% | -190% | -138% |
| Earnings per share | -$4.73 | -$4.63 | -$2.43 |
| Free cash flow | -$84.5M | -$100.5M | -$116.6M |
| Free cash margin | -304% | -168% | -123% |
| Cash | $8.2M | $237.6M | $99.7M |
| Long-term debt | $42.5M | $41.1M | $42.6M |
| Shareholders' equity | -$209.4M | $205.4M | $259.7M |
| Shares outstanding | 105.81k | 51.35m | 58.38m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Sep 14, 2026 | Quarterly ↗ | Jul 31, 2026 | 45d |
| Jul 14, 2026 | Annual ↗ | Apr 30, 2026 | 75d |
| Mar 17, 2026 | Quarterly ↗ | Jan 31, 2026 | 45d |
| Dec 11, 2025 | Quarterly ↗ | Oct 31, 2025 | 41d |
| Sep 12, 2025 | Quarterly ↗ | Jul 31, 2025 | 43d |
| Jul 17, 2025 | Annual ↗ | Apr 30, 2025 | 78d |
| Apr 17, 2025 | Quarterly ↗ | Jan 31, 2025 | 76d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 14, 2026 | Results ↗ |
| Sep 10, 2026 | Shareholder vote ↗ |
| Jul 14, 2026 | Material agreement · Agreement ended · Results · New obligation ↗ |
| Mar 17, 2026 | Results ↗ |
| Dec 11, 2025 | Results ↗ |
| Dec 4, 2025 | Material agreement ↗ |
| Dec 1, 2025 | Results ↗ |
| Nov 10, 2025 | Regulation FD ↗ |
| Sep 11, 2025 | Results ↗ |
| Sep 4, 2025 | Shareholder vote ↗ |
| Jul 15, 2025 | Results ↗ |
| Jun 6, 2025 | Director or officer change ↗ |